Human monoclonal antibody targeting the O-antigen protects against multidrug-resistant Klebsiella pneumoniae complex
mBio · 20.11.2026
DOI: 10.1128/mbio.02083-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, online erschienen am 20.11.2026. Verfasst von Camila Boniche-Alfaro und 4 weiteren Autor:innen. Die Arbeit nennt 83 Literaturangaben. Gefördert von: U.S. Department of Veterans Affairs, National Institutes of Health, Korea National Institute of Health.
Abstract (Originalsprache)
Klebsiella pneumoniae (Kp) are encapsulated gram-negative bacteria that cause healthcare-associated and severe community-acquired infections. The global emergence of carbapenem-resistant strains has led the World Health Organization to designate K. pneumoniae a “critical priority” pathogen. This study aimed to identify human monoclonal antibodies (mAbs) with therapeutic potential against multidrug-resistant K. pneumoniae . Using a target-agnostic strategy, we selected human mAbs elicited during an asymptomatic infection with K. pneumoniae . We evaluated the antibody binding to bacterial surface antigens by enzyme-linked immunosorbent assay (ELISA), analytical flow cytometry, and immunoblotting. In vitro , the mAbs were tested by complement-mediated killing and macrophage uptake assays using Kp clinical isolates of differing serotypes. Finally, we evaluated the therapeutic efficacy of the mAbs in a murine pneumonia model with carbapenem-resistant K. pneumoniae . Among the four IgG antibodies identified, mAbKPNA-14 demonstrated specific binding to K. pneumoniae wzi 50:O3b and cross-reactivity with O-antigen type O3/O3a. mAbKPNA-14 significantly enhanced complement-mediated killing ( p < 0.01) and macrophage phagocytosis. In vivo , the therapeutic administration of mAbKPNA-14 reduced bacterial load in the lungs by over 100-fold compared to the control groups ( p < 0.001) and prevented systemic dissemination. This study describes a human mAb that binds to O3b and O3/O3a O-antigens and confers in vivo protection against drug-resistant K. pneumoniae . These findings support the therapeutic potential of mAbs and describe a strategy for isolating and identifying protective mAbs targeting multidrug-resistant bacteria. IMPORTANCE Multidrug-resistant Klebsiella pneumoniae is a critical global health threat for which new therapeutic approaches are urgently needed. Here, we identify a naturally elicited human monoclonal antibody, mAbKPNA-14, which recognizes the O3b O-antigen and cross-reacts with related O3/O3a O-antigens. The antibody promotes complement-mediated killing and macrophage uptake and, when administered therapeutically, reduces pulmonary bacterial burden by more than 100-fold and prevents systemic dissemination in a mouse model of carbapenem-resistant K. pneumoniae pneumonia. These findings demonstrate that protective human antibodies can be isolated directly from individuals following K. pneumoniae infection and identify O-antigen as a promising target for antibody-based therapy. More broadly, our target-agnostic approach provides a strategy for discovering naturally occurring protective antibodies against multidrug-resistant bacterial pathogens.
Förderung
- U.S. Department of Veterans Affairs
- National Institutes of Health
- Korea National Institute of Health
Zitieren
APA
Boniche-Alfaro, C., Fowler, B. D., Mihooliya, K. N., Crowe, J. E., & Fries, B. C. (2026). Human monoclonal antibody targeting the O-antigen protects against multidrug-resistant Klebsiella pneumoniae complex. mBio. https://doi.org/10.1128/mbio.02083-26
Vancouver
Boniche-Alfaro C, Fowler BD, Mihooliya KN, Crowe JE, Fries BC. Human monoclonal antibody targeting the O-antigen protects against multidrug-resistant Klebsiella pneumoniae complex. mBio. 2026. doi:10.1128/mbio.02083-26
BibTeX
@article{BonicheAlfaro2026,
author = {Boniche-Alfaro, Camila and Fowler, Benjamin D. and Mihooliya, Kanti N. and Crowe, James E. and Fries, Bettina C.},
title = {Human monoclonal antibody targeting the O-antigen protects against multidrug-resistant Klebsiella pneumoniae complex},
journal = {mBio},
year = {2026},
doi = {10.1128/mbio.02083-26}
}
EUVIMED